Demographic data, JAK2V617F-status, and other characteristics of MPD patients
| Disease . | No. . | Age at diagnosis, y* . | No. of men (%) . | JAK2V617F+, no. (%) . | JAK2V617F-HOM, no. (%) . | Diagnosis to JAK2V617F test, mo* . |
|---|---|---|---|---|---|---|
| PV | 84 | 56 (16-84) | 40 (48) | 79 (94) | 22 (28) | 12 (0-552) |
| PMF | 58 | 58 (18-80) | 40 (69) | 28 (48) | 7 (25) | 21 (0-324) |
| ET | 37 | 47 (17-81) | 15 (41) | 19 (51) | 1 (5) | 11 (0-240) |
| Disease . | No. . | Age at diagnosis, y* . | No. of men (%) . | JAK2V617F+, no. (%) . | JAK2V617F-HOM, no. (%) . | Diagnosis to JAK2V617F test, mo* . |
|---|---|---|---|---|---|---|
| PV | 84 | 56 (16-84) | 40 (48) | 79 (94) | 22 (28) | 12 (0-552) |
| PMF | 58 | 58 (18-80) | 40 (69) | 28 (48) | 7 (25) | 21 (0-324) |
| ET | 37 | 47 (17-81) | 15 (41) | 19 (51) | 1 (5) | 11 (0-240) |
MPD indicates myeloproliferative disorders; PV, polycythemia vera; PMF, primary myelofibrosis; ET, essential thrombocythemia; HOM, homozygous (by polymerase chain reaction sequencing of granulocyte DNA).
Values are median (range).